<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1064">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093025</url>
  </required_header>
  <id_info>
    <org_study_id>TS121-US201</org_study_id>
    <nct_id>NCT03093025</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Patients With Major Depressive Disorder With an Inadequate Response to Current Antidepressant Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical R&amp;D Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and efficacy of TS-121 as
      an adjunctive treatment for patients with major depressive disorder with an inadequate
      response to current antidepressant Treatment (SSRI or SNRI).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in MADRS total score from Baseline to End of Treatment estimated for 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Scale (HAM-A)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in HAM-A total score from Baseline to End of Treatment estimated for 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of Depression Questionnaire (SDQ)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in SDQ total score from Baseline to End of Treatment estimated for 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Severity (CGI-S)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in CGI-S score from Baseline to End of Treatment estimated for 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of MADRS responders (≥ 50% reduction in total score) estimated for 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Improvement (CGI-I)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of CGI-I improvers (&quot;Very much improved&quot; or &quot;Much improved&quot;) estimated for 8 weeks</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>TS-121 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TS-121 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-121 10 mg</intervention_name>
    <description>Orally taken once daily</description>
    <arm_group_label>TS-121 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-121 50 mg</intervention_name>
    <description>Orally taken once daily</description>
    <arm_group_label>TS-121 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Orally taken once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult males and females between 18 and 65 years of age inclusive (at time of initial
             informed consent)

          2. Patients with a current diagnosis of MDD by DSM-5, confirmed through a structured
             interview using MINI

          3. Patients who receive the same antidepressant (SSRI or SNRI monotherapy) for at least
             6 weeks of continuous treatment with at least 4 weeks on a fixed dose

          4. Patients who willing to remain on the same primary SSRI or SNRI and fixed dose
             throughout the course of the study

          5. Patients who meet the total score on the HAM-D as listed below

               1. HAM-D ≥ 21 at Screening

               2. HAM-D ≤ 25% improvement during Placebo Lead-in period

               3. HAM-D ≥ 18 at End of Placebo Lead-in period

          6. Body Mass Index (BMI) ≥ 18 and ≤ 35 kg/m2

        Exclusion Criteria:

          1. Patients with inadequate response to ≥2 prior antidepressant treatments (not
             including current antidepressant) of at least 4 weeks duration each for the current
             episode

          2. Patients whose current depressive episode is diagnosed with psychotic features,
             catatonic features, post-partum (primary onset), or is secondary to a general medical
             disorder

          3. Patients with a diagnosis of any of the following DSM-5 class disorders

               1. Schizophrenia spectrum and other psychotic disorders

               2. Bipolar and related disorders

               3. Anxiety disorders

               4. Obsessive-compulsive and related disorders

               5. Trauma- and Stressor-related disorders

          4. Patients who received electroconvulsive therapy (ECT) within 12 months of Screening,
             received more than one course of ECT in their lifetime or plan to receive ECT during
             the study

          5. Patients who received repetitive transcranial magnetic stimulation (rTMS) within 12
             months of Screening or plan to receive rTMS during the study

          6. Patients who plan to initiate or terminate cognitive or behavioral psychotherapy or
             alter the frequency of ongoing therapy during this study

          7. Patients who have attempted suicide within the past 6 months

          8. Patients with history or presence of intellectual disability, pervasive developmental
             disorder, cognitive disorder, neurodegenerative disorder, or brain injury

          9. Patients with any history or complication of convulsive disorder

         10. Patients who are undergoing treatment with psychotropic medications, benzodiazepines,
             metyrapone, lithium and/or corticosteroids

         11. Patients who are taking moderate to strong CYP3A4 inhibitors/inducers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Taisho Pharmaceutical R&amp;D Inc.</last_name>
    <email>ClinicalTrials@taisho-rd.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PAREXEL Early Phase Clinical Unit</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>March 15, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Adjunctive Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
